세계의 전이성 요로상피암 시장 보고서(2025년)

Metastatic Urothelial Carcinoma Global Market Report 2025

US $ 4,490 ￦ 6,253,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,039,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,824,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

전이성 요로상피암 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년에는 19.9%의 연평균 복합 성장률(CAGR)로 29억 4,000만 달러에 달할 것으로 예측됩니다. 예측 기간의 성장은 환자 옹호 증가, 암 치료를 지원하는 정부 프로그램, 바이오 제약 산업의 성장, 화학 요법의 적용 확대, 급속한 도시화 및 라이프 스타일 변화에 기인합니다. 이 기간 동안 예상되는 주요 동향으로는 면역치료의 발전, 인공지능의 통합, 제약회사와 바이오테크 기업의 제휴, 원격의료의 발전, 차세대 의약품의 개발 등이 있습니다.

방광암 발병률 증가는 전이성 요로상피암 시장의 성장을 견인할 것으로 예측됩니다. 방광암은 방광 조직에 악성 세포가 형성되는 질환으로 일반적으로 방광을 덮고 있는 요로상피세포에서 시작됩니다. 방광암 환자 증가는 흡연, 화학물질 노출, 만성 방광 염증, 검출 방법의 개선 등의 요인에 기인합니다. 전이성 요로상피암은 방광암의 진행성 및 침습성 병기를 나타내므로 조기 발견, 더 나은 치료법, 연구 증가의 필요성을 강조하고 궁극적으로 방광암 관리의 혁신을 촉진하고 환자의 결과를 개선할 수 있습니다. 예를 들어, Cancer Research UK의 2023년 2월 보고서에 따르면, 영국의 신규 방광암 발병 건수는 2023-2025년 연간 약 9,800건에서 2038-2040년 연간 약 10,700건으로 증가할 것으로 예측됩니다. 이러한 방광암의 유병률 증가가 전이성 요로상피암 시장의 성장을 견인하고 있습니다.

또한, 새로운 치료법에 대한 규제 당국의 승인도 시장 성장에 기여하고 있습니다. 전이성 요로상피암 분야의 주요 기업들은 약사 승인을 획득하여 시장 범위를 확장하고 국소 진행성 또는 전이성 요로상피암(la/mUC) 성인 환자 치료에서 입지를 강화하고 있습니다. 약사 승인은 정부 기관이 의약품이나 치료법이 일반인에게 판매될 수 있도록 공식적으로 허가하는 것을 의미합니다. 예를 들어, 2023년 4월 미국 제약회사 머크(Merck &Co.Inc.)는 KEYTRUDA(펨브롤리주맙)를 국소 진행성 또는 전이성 요로상피암 환자의 1차 치료제로 FDA의 승인을 획득했습니다. enfortumab vedotin 병용요법은 국소 진행성 또는 전이성 요로상피암 환자를 위한 항체-약물 복합제 병용요법으로 미국에서 승인된 최초의 항 PD-1 요법으로, 이번 승인은 요로상피암 치료에 있어 중요한 진일보를 이룬 것입니다. 이 병용요법은 기존 백금 기반 화학요법 대비 전체 생존기간(OS) 및 무진행 생존기간(PFS)에서 통계적으로 유의미한 개선을 보여 치료 옵션이 제한적인 환자들에게 새로운 치료옵션을 제공했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 전이성 요로상피암PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 전이성 요로상피암 시장 : 성장률 분석
• 세계의 전이성 요로상피암 시장 실적 : 규모와 성장, 2019-2024
• 세계의 전이성 요로상피암 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 전이성 요로상피암 전체 시장(TAM)

제6장 시장 세분화

• 세계의 전이성 요로상피암 시장 : 치료별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 화학요법
• 표적치료
• 면역치료
• 방사선 치료
• 방광내 요법
• 세계의 전이성 요로상피암 시장 : 진단별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 요검사
• 방광경 검사
• 정맥성 신우조영(IVP)
• 생검
• 세계의 전이성 요로상피암 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 종양학 클리닉
• 연구기관
• 기타 최종사용자
• 세계의 전이성 요로상피암 시장 : 화학요법 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 플래티넘 제제 화학요법
• 젬시타빈 기반 화학요법
• 기타 화학요법 레지멘
• 세계의 전이성 요로상피암 시장 : 표적치료 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• FGFR 억제제
• 면역 관문 억제제
• 기타 표적 에이전트
• 세계의 전이성 요로상피암 시장 : 면역요법 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• PD-1 또는 PD-L1 억제제
• CTLA-4 억제제
• 복합 면역치료
• 세계의 전이성 요로상피암 시장 : 방사선 치료 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 외부 방사선 요법
• 정위 방사선 치료
• 세계의 전이성 요로상피암 시장 : 방광내 요법 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Bacillus Calmette-Guerin Therapy
• Chemotherapy-based Intravesical Therapy

제7장 지역별/국가별 분석

• 세계의 전이성 요로상피암 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 전이성 요로상피암 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 전이성 요로상피암 시장 : 경쟁 구도
• 전이성 요로상피암 시장 : 기업 개요
  • Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Johnson & Johnson Services Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co., Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Bayer AG
• Bayer Aktiengesellschaft
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Eli Lilly and Company
• Gilead Sciences Inc.
• Merck KGaA
• Astellas Pharma Inc.
• Genentech Inc.
• Genentech Inc.
• Exelixis Inc.
• EMD Serono
• Zymeworks Inc.
• Mirati Therapeutics Inc.
• UroGen Pharma Ltd.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 전이성 요로상피암 시장(2029년) : 새로운 기회를 제공하는 국가
• 전이성 요로상피암 시장(2029년) : 새로운 기회를 제공하는 부문
• 전이성 요로상피암 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Metastatic urothelial carcinoma is an advanced form of bladder cancer where the cancer has spread beyond the urothelium to distant organs or lymph nodes. Treatment for metastatic urothelial carcinoma involves advanced diagnostic technologies, targeted therapies, and immunotherapies to manage and treat cancer that has spread beyond the bladder or urinary tract.

The primary treatment options for metastatic urothelial carcinoma include chemotherapy, targeted therapy, immunotherapy, radiation therapy, and intravesical therapy. Chemotherapy uses drugs to kill cancer cells or inhibit their growth. Diagnostic methods for detecting this cancer include urine lab tests, cystoscopy, intravenous pyelogram (IVP), and biopsy. Treatments can include medications, lifestyle changes, and other therapies, with administration routes such as oral, parenteral, and others. These treatments are utilized in various settings, including hospitals, oncology clinics, research institutes, and other healthcare facilities.

The metastatic urothelial carcinoma market research report is one of a series of new reports from The Business Research Company that provides metastatic urothelial carcinoma market statistics, including metastatic urothelial carcinoma industry global market size, regional shares, competitors with a metastatic urothelial carcinoma market share, detailed metastatic urothelial carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic urothelial carcinoma industry. This metastatic urothelial carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metastatic urothelial carcinoma market size has grown exponentially in recent years. It will grow from $1.18 billion in 2024 to $1.42 billion in 2025 at a compound annual growth rate (CAGR) of 20.2%. The growth during the historic period can be attributed to a favorable regulatory environment, the rising incidence of smoking-related cancers, the emergence of combination therapies, supportive government policies, and increased awareness and early diagnosis of metastatic urothelial carcinoma.

The metastatic urothelial carcinoma market size is expected to see rapid growth in the next few years. It will grow to $2.94 billion in 2029 at a compound annual growth rate (CAGR) of 19.9%. The growth in the forecast period can be attributed to increased patient advocacy, government programs supporting cancer care, the growth of the biopharmaceutical industry, the rising application of chemotherapy, and rapid urbanization and lifestyle changes. Major trends expected during this period include advancements in immunotherapy, the integration of artificial intelligence, collaborations between pharmaceutical and biotech companies, advancements in telemedicine, and the development of next-generation drugs.

The increasing incidence of bladder cancer is expected to drive the growth of the metastatic urothelial carcinoma market. Bladder cancer is a condition where malignant cells form in the bladder tissues, typically starting in the urothelial cells lining the bladder. The rise in bladder cancer cases is attributed to factors such as smoking, chemical exposure, chronic bladder inflammation, and improvements in detection methods. As metastatic urothelial carcinoma represents an advanced and aggressive stage of bladder cancer, it highlights the critical need for early detection, better treatment options, and increased research, ultimately fostering innovations in the management of bladder cancer and improving patient outcomes. For example, according to a February 2023 report from Cancer Research UK, the number of new bladder cancer cases in the UK is projected to rise from about 9,800 annually between 2023 and 2025 to around 10,700 cases per year by 2038-2040. This growing prevalence of bladder cancer is driving the expansion of the metastatic urothelial carcinoma market.

Regulatory approvals for new treatments are also contributing to the market's growth. Major companies in the metastatic urothelial carcinoma space are obtaining regulatory approvals for drugs, expanding their market reach and reinforcing their position in treating adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Regulatory approvals involve the formal authorization granted by governmental bodies for drugs or treatments to be marketed to the public. For example, in April 2023, Merck & Co. Inc., a US-based pharmaceutical company, received FDA approval for KEYTRUDA (pembrolizumab) as a first-line treatment for certain patients with locally advanced or metastatic urothelial cancer. This approval marks a significant step in urothelial cancer treatment, as the combination of KEYTRUDA (pembrolizumab) and enfortumab vedotin became the first anti-PD-1 therapy approved in the U.S. in combination with an antibody-drug conjugate for patients with locally advanced or metastatic urothelial cancer. The combination therapy demonstrated a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) when compared to traditional platinum-based chemotherapy, offering a new option for patients with limited treatment alternatives.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for an undisclosed amount. This acquisition enables Pfizer to enhance its oncology portfolio by integrating Seagen's innovative antibody-drug conjugate (ADC) technology and expanding its ability to develop targeted cancer therapies. This move strengthens Pfizer's leadership in cancer treatment and broadens its oncology product pipeline. Seagen, a US-based biotechnology company, specializes in therapies for metastatic urothelial carcinoma.

Major players in the metastatic urothelial carcinoma market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., Bayer AG, Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc., Merck KGaA, Astellas Pharma Inc., Genentech Inc., Genentech Inc., Exelixis Inc., EMD Serono, Zymeworks Inc., Mirati Therapeutics Inc., UroGen Pharma Ltd.

North America was the largest region in the metastatic urothelial carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metastatic urothelial carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic urothelial carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metastatic urothelial carcinoma market consists of revenues earned by entities by providing services such as sales of surgical treatment, combination therapy and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic urothelial carcinoma market also includes sales of chemotherapy agents, immunotherapy drugs, tyrosine kinase inhibitors, adjuvant treatments, and targeted therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Urothelial Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic urothelial carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metastatic urothelial carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metastatic urothelial carcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Chemotherapy; Targeted Therapy; Immunotherapy; Radiation Therapy; Intravesical Therapy
• 2) By Diagnosis: Urine Lab Tests; Cystoscopy; Intravenous Pyelogram (IVP); Biopsy
• 3) By End User: Hospital; Oncology Clinics; Research Institutes; Other End User
• Subsegments:
• 1) By Chemotherapy: Platinum-based Chemotherapy; Gemcitabine-based Chemotherapy; Other Chemotherapy Regimens
• 2) By Targeted Therapy: FGFR Inhibitors; Immune Checkpoint Inhibitors; Other Targeted Agents
• 3) By Immunotherapy: PD-1 Or PD-L1 Inhibitors; CTLA-4 Inhibitors; Combination Immunotherapies
• 4) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy
• 5) By Intravesical Therapy: Bacillus Calmette-Guerin Therapy; Chemotherapy-based Intravesical Therapy
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metastatic Urothelial Carcinoma Market Characteristics

3. Metastatic Urothelial Carcinoma Market Trends And Strategies

4. Metastatic Urothelial Carcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Metastatic Urothelial Carcinoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metastatic Urothelial Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metastatic Urothelial Carcinoma Market Growth Rate Analysis
• 5.4. Global Metastatic Urothelial Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metastatic Urothelial Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metastatic Urothelial Carcinoma Total Addressable Market (TAM)

6. Metastatic Urothelial Carcinoma Market Segmentation

• 6.1. Global Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• Intravesical Therapy
• 6.2. Global Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urine Lab Tests
• Cystoscopy
• Intravenous Pyelogram (IVP)
• Biopsy
• 6.3. Global Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Oncology Clinics
• Research Institutes
• Other End Users
• 6.4. Global Metastatic Urothelial Carcinoma Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Platinum-based Chemotherapy
• Gemcitabine-based Chemotherapy
• Other Chemotherapy Regimens
• 6.5. Global Metastatic Urothelial Carcinoma Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• FGFR Inhibitors
• Immune Checkpoint Inhibitors
• Other Targeted Agents
• 6.6. Global Metastatic Urothelial Carcinoma Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PD-1 Or PD-L1 Inhibitors
• CTLA-4 Inhibitors
• Combination Immunotherapies
• 6.7. Global Metastatic Urothelial Carcinoma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy
• Stereotactic Body Radiation Therapy
• 6.8. Global Metastatic Urothelial Carcinoma Market, Sub-Segmentation Of Intravesical Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bacillus Calmette-Guerin Therapy
• Chemotherapy-based Intravesical Therapy

7. Metastatic Urothelial Carcinoma Market Regional And Country Analysis

• 7.1. Global Metastatic Urothelial Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metastatic Urothelial Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metastatic Urothelial Carcinoma Market

• 8.1. Asia-Pacific Metastatic Urothelial Carcinoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metastatic Urothelial Carcinoma Market

• 9.1. China Metastatic Urothelial Carcinoma Market Overview
• 9.2. China Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metastatic Urothelial Carcinoma Market

• 10.1. India Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metastatic Urothelial Carcinoma Market

• 11.1. Japan Metastatic Urothelial Carcinoma Market Overview
• 11.2. Japan Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metastatic Urothelial Carcinoma Market

• 12.1. Australia Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metastatic Urothelial Carcinoma Market

• 13.1. Indonesia Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metastatic Urothelial Carcinoma Market

• 14.1. South Korea Metastatic Urothelial Carcinoma Market Overview
• 14.2. South Korea Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metastatic Urothelial Carcinoma Market

• 15.1. Western Europe Metastatic Urothelial Carcinoma Market Overview
• 15.2. Western Europe Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metastatic Urothelial Carcinoma Market

• 16.1. UK Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metastatic Urothelial Carcinoma Market

• 17.1. Germany Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metastatic Urothelial Carcinoma Market

• 18.1. France Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metastatic Urothelial Carcinoma Market

• 19.1. Italy Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metastatic Urothelial Carcinoma Market

• 20.1. Spain Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metastatic Urothelial Carcinoma Market

• 21.1. Eastern Europe Metastatic Urothelial Carcinoma Market Overview
• 21.2. Eastern Europe Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metastatic Urothelial Carcinoma Market

• 22.1. Russia Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metastatic Urothelial Carcinoma Market

• 23.1. North America Metastatic Urothelial Carcinoma Market Overview
• 23.2. North America Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metastatic Urothelial Carcinoma Market

• 24.1. USA Metastatic Urothelial Carcinoma Market Overview
• 24.2. USA Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metastatic Urothelial Carcinoma Market

• 25.1. Canada Metastatic Urothelial Carcinoma Market Overview
• 25.2. Canada Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metastatic Urothelial Carcinoma Market

• 26.1. South America Metastatic Urothelial Carcinoma Market Overview
• 26.2. South America Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metastatic Urothelial Carcinoma Market

• 27.1. Brazil Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metastatic Urothelial Carcinoma Market

• 28.1. Middle East Metastatic Urothelial Carcinoma Market Overview
• 28.2. Middle East Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metastatic Urothelial Carcinoma Market

• 29.1. Africa Metastatic Urothelial Carcinoma Market Overview
• 29.2. Africa Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metastatic Urothelial Carcinoma Market Competitive Landscape And Company Profiles

• 30.1. Metastatic Urothelial Carcinoma Market Competitive Landscape
• 30.2. Metastatic Urothelial Carcinoma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co., Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Metastatic Urothelial Carcinoma Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Bayer Aktiengesellschaft
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca PLC
• 31.5. Eli Lilly and Company
• 31.6. Gilead Sciences Inc.
• 31.7. Merck KGaA
• 31.8. Astellas Pharma Inc.
• 31.9. Genentech Inc.
• 31.10. Genentech Inc.
• 31.11. Exelixis Inc.
• 31.12. EMD Serono
• 31.13. Zymeworks Inc.
• 31.14. Mirati Therapeutics Inc.
• 31.15. UroGen Pharma Ltd.

32. Global Metastatic Urothelial Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic Urothelial Carcinoma Market

34. Recent Developments In The Metastatic Urothelial Carcinoma Market

35. Metastatic Urothelial Carcinoma Market High Potential Countries, Segments and Strategies

• 35.1 Metastatic Urothelial Carcinoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metastatic Urothelial Carcinoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metastatic Urothelial Carcinoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료